TG Therapeutics Inc Total Liabilities
TG Therapeutics Inc total liabilities. Based on the latest financial reports, TG Therapeutics Inc (TGTX) has total liabilities worth $1.04 Billion USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check TGTX cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of TG Therapeutics Inc (1996–2025)
Total liabilities of TG Therapeutics Inc from 1996 to 2025. This chart illustrates how TG Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore how much of TG Therapeutics Inc's assets are long-term investments to see how much of total assets are deployed in long-term investments.
TG Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of TG Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
StandardAero, Inc.
NYSE:SARO
|
USA | $4.02 Billion |
|
Piraeus Financial Holdings S.A
AT:TPEIR
|
Greece | €72.38 Billion |
|
Quinenco
SN:QUINENCO
|
Chile | CL$52.97 Trillion |
|
Western Alliance Bancorporation
NYSE:WAL
|
USA | $90.57 Billion |
|
Blueprint Medicines Corp
NASDAQ:BPMC
|
USA | $853.47 Million |
|
Restaurant Brands International Limited Partnership
TO:QSP-UN
|
Canada | CA$19.59 Billion |
|
Svenska Cellulosa Aktiebolaget SCA (publ)
ST:SCA-B
|
Sweden | Skr44.94 Billion |
|
Redeia Corporacion S.A.
MC:RED
|
Spain | €10.33 Billion |
Liability Composition Analysis (1996–2025)
This chart breaks down TG Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see TG Therapeutics Inc (TGTX) total assets.
Liquidity & Leverage Metrics
TG Therapeutics Inc Total Liabilities Ratios Explained
TG Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.27 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.71 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.63 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how TG Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for TG Therapeutics Inc (1996–2025)
The table below shows the annual total liabilities of TG Therapeutics Inc from 1996 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $415.23 Million | +16.86% |
| 2024-12-31 | $355.33 Million | +110.15% |
| 2023-12-31 | $169.09 Million | +25.26% |
| 2022-12-31 | $134.99 Million | -5.26% |
| 2021-12-31 | $142.48 Million | +34.04% |
| 2020-12-31 | $106.29 Million | -14.56% |
| 2019-12-31 | $124.40 Million | +108.79% |
| 2018-12-31 | $59.58 Million | -38.82% |
| 2017-12-31 | $97.38 Million | +77.76% |
| 2016-12-31 | $54.78 Million | -51.72% |
| 2015-12-31 | $113.47 Million | +30.81% |
| 2014-12-31 | $86.75 Million | +80.30% |
| 2013-12-31 | $48.11 Million | +637.50% |
| 2012-12-31 | $6.52 Million | +4.03% |
| 2011-12-31 | $6.27 Million | -73.87% |
| 2010-12-31 | $24.00 Million | +235.63% |
| 2009-12-31 | $7.15 Million | +27.12% |
| 2008-12-31 | $5.62 Million | +200.53% |
| 2007-12-31 | $1.87 Million | -3.69% |
| 2006-12-31 | $1.94 Million | +16.66% |
| 2005-12-31 | $1.67 Million | +39.32% |
| 2004-12-31 | $1.20 Million | +23.78% |
| 2003-12-31 | $966.02K | +67.21% |
| 2002-12-31 | $577.73K | +13.59% |
| 2001-12-31 | $508.61K | -75.55% |
| 2000-12-31 | $2.08 Million | +246.74% |
| 1999-12-31 | $600.00K | 0.00% |
| 1998-12-31 | $600.00K | +50.00% |
| 1997-12-31 | $400.00K | +33.33% |
| 1996-12-31 | $300.00K | -- |
About TG Therapeutics Inc
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolat… Read more